Signal transducer and activator of transcription 3 is a major kinase-independent _target of sorafenib in hepatocellular carcinoma
- PMID: 21354226
- DOI: 10.1016/j.jhep.2011.01.047
Signal transducer and activator of transcription 3 is a major kinase-independent _target of sorafenib in hepatocellular carcinoma
Erratum in
-
Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent _target of sorafenib in hepatocellular carcinoma".J Hepatol. 2017 Mar;66(3):666-668. doi: 10.1016/j.jhep.2016.12.007. Epub 2017 Jan 6. J Hepatol. 2017. PMID: 28069352 No abstract available.
Abstract
Background & aims: Recently, we reported that sorafenib sensitizes hepatocellular carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of transcription 3 (STAT3). Here, we report that sorafenib inhibits HCC via a kinase-independent mechanism: SHP-1 dependent STAT3 inactivation.
Methods: SC-1 is a sorafenib derivative that closely resembles sorafenib structurally but with no kinase inhibition activity. HCC cell lines (PLC5, Huh-7, Hep3B, and Sk-Hep1) were treated with sorafenib or SC-1 and apoptosis and signal transduction were analyzed. In vivo efficacy was determined in nude mice with Huh-7 xenografts.
Results: SC-1 showed similar effects to sorafenib on growth inhibition and apoptosis in all tested HCC cell lines. SC-1 down-regulated phosphorylation of phospho-STAT3 (p-STAT3) at tyrosine 705 in all tested HCC cells. Expression of STAT3-driven genes, including Cyclin D1 and Survivin, was also repressed by SC-1. Luciferase reporter assay confirmed the inhibition of transcriptional activity of STAT3 in both sorafenib-treated and SC-1-treated cells. Ectopic expression of STAT3 in PLC5 cells abolished apoptosis in SC-1-treated cells. Sorafenib and SC-1 up-regulated SHP-1 activity. Knockdown of SHP-1, but not SHP-2 or PTP-1B, by small interference RNA reduced apoptosis induced by SC-1. Finally, SC-1 reduced Huh-7 tumor growth significantly in vivo, which was associated with down-regulation of p-STAT3 and up-regulation of SHP-1 activity.
Conclusions: STAT3 is a major kinase-independent _target of sorafenib in HCC.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Comment in
-
_targeting STAT3 in hepatocellular carcinoma: sorafenib again….J Hepatol. 2011 Nov;55(5):957-9. doi: 10.1016/j.jhep.2011.06.005. Epub 2011 Jun 28. J Hepatol. 2011. PMID: 21718664 No abstract available.
Similar articles
-
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.Mol Cancer Ther. 2012 Feb;11(2):452-63. doi: 10.1158/1535-7163.MCT-11-0412. Epub 2011 Dec 16. Mol Cancer Ther. 2012. PMID: 22180308
-
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.J Thorac Oncol. 2014 Apr;9(4):488-96. doi: 10.1097/JTO.0000000000000107. J Thorac Oncol. 2014. PMID: 24736071
-
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.Cancer Lett. 2014 Jul 28;349(2):136-43. doi: 10.1016/j.canlet.2014.04.006. Epub 2014 Apr 13. Cancer Lett. 2014. PMID: 24735751
-
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.World J Gastroenterol. 2014 Nov 7;20(41):15269-74. doi: 10.3748/wjg.v20.i41.15269. World J Gastroenterol. 2014. PMID: 25386075 Free PMC article. Review.
-
PDGFRalpha: a new therapeutic _target in the treatment of hepatocellular carcinoma?Expert Opin Ther _targets. 2009 Apr;13(4):443-54. doi: 10.1517/14728220902719233. Expert Opin Ther _targets. 2009. PMID: 19335066 Review.
Cited by
-
Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Int J Cancer. 2017 Feb 1;140(3):705-717. doi: 10.1002/ijc.30446. Epub 2016 Nov 9. Int J Cancer. 2017. PMID: 27668844 Free PMC article.
-
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma.World J Hepatol. 2013 Jul 27;5(7):345-52. doi: 10.4254/wjh.v5.i7.345. World J Hepatol. 2013. PMID: 23898367 Free PMC article.
-
Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis.J Int Med Res. 2020 Aug;48(8):300060520946872. doi: 10.1177/0300060520946872. J Int Med Res. 2020. PMID: 32815430 Free PMC article.
-
Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways.Onco_target. 2015 Apr 30;6(12):10116-33. doi: 10.18632/onco_target.2687. Onco_target. 2015. PMID: 25426556 Free PMC article.
-
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.World J Gastroenterol. 2014 Apr 21;20(15):4151-9. doi: 10.3748/wjg.v20.i15.4151. World J Gastroenterol. 2014. PMID: 24764653 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous